Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Similar documents
FDA Audit Preparation

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Compliance and Quality Monitoring: What, Why, When, and How

Effective Date: October 8, 2015 Policy Number: MHC_RP0301. Corporate Director, HRPP Institutional Official, HRPP

K E M R I STANDARD OPERATING PROCEDURE FOR ROUTINE AND FOR- CAUSE AUDITS

ELEMENTS OF A DATA MONITORING PLAN

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018

FDA Audit Preparation

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

Implementing Good Clinical Practice at an Academic Research Institution

Standard Operating Procedures Guidelines for Good Clinical Practice

13.0 Quality Improvement in the HRPP Program

BACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING

HUMAN RESEARCH PROTECTION PROGRAM PLAN

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Human Research Protection Program Policy

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH

Investigator Site File Index (CTIMP)

Source And Regulatory Documentation for DMID Clinical Studies

Human Research Protection Program Compliance Plan

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

RESEARCH AUDIT Standard Operating Procedure

Good Clinical Practice

FDA Sponsor and Investigator Responsibility Checklist

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ

Standard Operating Procedure

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

Sponsor-Investigator Responsibilities In Clinical Trials

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

Standard Operating Procedures (SOPs)

GCP Convergence Improves Transportability of Medical Device Clinical Data

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

1.0 INTRODUCTION AND OVERVIEW

STANDARD OPERATING PROCEDURE

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

Human Subjects Protection Program Plan

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Investigator Manual. Human Subjects Protection Program

Investigator Site File Index (Medical Devices)

VCU Faculty Held IND and IDE Procedure Handbook

Human Research Protection Program. Plan

GW Policy on Human Research Protection Program

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Regulatory Binder: Set-up and Maintenance

Introduction to Clinical Research

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

Stephanie Gentilin, CCRA

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

Clinical Trials & Regulatory

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

I. Purpose. II. Definitions. Last Approval Date

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE

Advocate Health Care Network. Human Research Protection Program. Plan

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

SELF-ASSESSMENT CHECKLIST

Human Research Protection Program Plan

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005

Hub Performance Assessment

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

3.0 HSC Relation to Other KUMC Committees

Investigator-Initiated INDs

Date: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014

Louise Brook Clinical Trials Quality Monitor. Date

Human Research Protection Program. Investigator Manual

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

Embryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration

Study Management SM STANDARD OPERATING PROCEDURE FOR Specimen Management

External IRB Review What Does it Mean for Your Institution

DTE ENERGY COMPANY AUDIT COMMITTEE CHARTER

IEC Best Practices: Standard Operating Procedures

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:

Conducting Clinical Trials of Investigational Medicinal Products

Clinical Trials Management for Molecular Diagnostics. April 2016

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

Audit Program Background Definition Management Example Content Risk assessment approach

ClinicalTrials.gov Updates. Gabrielle Gaspard Assistant Director Human Research Compliance

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.

Indiana University, Purdue University Indianapolis Institutional Biosafety Committee (IBC) Policy & Procedure Manual.

Standard Operating Procedure. GCP Auditing of Research Studies

Guidelines for Setting Up a Regulatory Binder

Inspections: an academic perspective

Index of Standard Operating Procedures for all research Sponsored by the UHL

GCP/Clinical Investigation in Japan

ICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄

End of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:

Institutional Biosafety Committee

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

Transcription:

Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017

Objectives 1. Understand the purpose of the audit program 2. Identify the stakeholders and their roles and responsibilities 3. Describe the audit process, preparation, and reporting

What is an audit? A systematic and independent examination of trial related activities, documents and data to determine whether the IRB-approved protocol was followed and if subjects (ethical treatment) and data were appropriately managed (recorded, analyzed, and reported) per protocol and applicable regulatory requirements.

Purpose Joint collaboration between Human Research Compliance and JCTO to audit all active WCM IRB-approved protocols, regardless of funding source. Facilitate the ethical and regulatory-compliant conduct of human research and improve human subject protections by: ensuring the rights, safety, and well-being of participants in human research are properly protected in adherence to all applicable regulations. providing a mechanism to evaluate and categorize non-compliance promoting researchers accountability. ensuring integrity of study data. Proactively evaluate and establish standards to identify resources and constraints for the research community by collecting metrics for: monitoring emerging trends. developing and modifying institutional policies and training. provide Investigator-specific management and training. assist investigators with self-assessment tools for research compliance.

Types of Audits For-Cause Audit In-depth examination of all components of a research study Initiated due to substantive written or verbal allegation of noncompliance Not-For-Cause Routine Low level /absence of reporting to the IRB Less likely if a QAU or an external audit has been conducted in the past 2 years QAU Monitoring Same format as a routine audit Focuses on IITs and multi-site studies Informal basis Preparation for external auditors

Responsible Parties Human Research Compliance and JCTO Oversee and manage all audit activities. Report finding to PI, IRB, and Department Chair. Cultivate open communication to better support the research community. Principal Investigators Ensure research is conducted in compliance with the IRB approved protocol. Responsible for complete oversight and conduct of research. Ensure proper training and delegation of tasks to research staff. Are available and make accessible all required documents during an audit.

Responsible Parties (cont d) The Department Chair Confirm adequate resources are available to conduct the research safely and in compliance with all requirements. Ensure investigators are qualified. Request For-cause audit at any time IRB Provide final determination of noncompliance Request a For-Cause audit at any time Others Institutional Official Research Integrity Officer General Counsel Division Chiefs

Protocol Selection All active protocols are eligible for an audit, including exempt studies. Protocols are randomly selected to account for Tier of risk (negligible risk, low risk and greater-than-low risk) Control for repeated audits of the same protocol Length of audit may vary from several hours to days and is contingent upon the scope of the audit activities.

Sample Size Determination

Audit Notification For a routine Not-For-Cause audit, the audit team and the investigator will work on an agreed upon date. For-Cause audits may be unscheduled and/or occur without prior notice. PI will be notified by email of an audit and be provided with a preaudit preparation tool and an audit plan by the audit team. The audit plan outlines: Scope of Audit Date and type of audit activity Randomized list of subjects to be reviewed Request for access to database(s), etc.

Preparation Before an Audit ü Confirm audit date ü Review the audit plan ü Secure a private area for the auditor(s) to work ü Make accessible all requested documents for the audit ü Grant access to databases and shared drives to the auditor (s), if needed ü Be available for questions during the duration of the audit

What To Expect During An Audit Visit Pre and Post-Interview Review the site Standard Operating Procedures (SOPs), if applicable Review of Informed Consent Forms Survey Study Participants. Observation of informed consent by research team. Tour of Facility Verify control, storage, and accountability of investigational product (if applicable) and/or to confirm availability of related research equipment. Review study database to determine that data is collected in accordance with eirb application. Determine if the PI has a plan for record and data retention once study is completed.

What Are We Trying to Determine? Study Conduct Interviews with Principal Investigator, research staff members, and participants Review of regulatory binder, including IRB approvals Review of personnel credentials and training Tour and review of research facility and document storage Protocol Adherence Approved Protocol followed accordingly Participants inclusion and exclusion criteria Proper randomization Deviations Amendment(s) implemented accurately

What Are We Trying to Determine? Informed Consent Informed Consent Documentation Surveying research subjects enrolled in the study about their experiences as research participants Investigational Product/Device Thorough accountability Proper dispensing and dose modification Appropriate storage and destruction Subjects Records (Verification, Retention and Storage) Review of participant records for adherence to protocol Copies of clinical assessments and results Adverse events are assessed and reported Review of information security process

Survey Participants and Observation Informed Of Consent Process Review any written procedures (SOPs) regarding consenting process Interview research participant(s) Evaluate their overall comprehension of informed consent process PI or co-investigator involved in the consenting process and listed on eirb application Overall Compliance Were all subjects consented Were the appropriate versions of the ICF used at the correct time Are all forms signed and dated Copies in medical chart or EMR Copies provided to participants

After the Audit

Audit Report and PI s Response Prior to the written report, the auditor and PI will discuss the audit findings at the exit interview. PI receives an audit report within 3 weeks of the exit interview. The audit report may or may not identify any areas of reportable non-compliance. Principal Investigator must respond in writing to the audit report and is required to implement a corrective action plan (CAPA) commensurate with the degree of the noncompliance. The auditor may recommend specific items to include in the corrective actions plan. However, the PI may choose whether or not to implement the recommendations or provide his/her own. Principal Investigator must submit a corrective action plan to the audit team within 21 days of the receipt of the audit letter. The audit report containing the PI s response is provided to the IRB and presented at a convene board meeting. IRB makes final IRB determination of compliance and the letter is distributed to the Principal Investigator, Assistant Dean of Human Research Compliance, Associate Dean of Clinical Research and Department Chair.

Examples of IRB Determinations Accept the PI s CAPA with no further requests. Issue additional corrective actions. Restrict research of the PI or limit the amount of activity on certain projects. Suspend or terminate one or more research projects conducted by the PI. Require educational sessions for the PI and research team. Suspend enrollment of new study participants on one or more research projects conducted by the PI. Require additional reporting to the IRB or conducting early Continuing Review. Require re-reviewing of research by the IRB, DSMB, or CSEC (Clinical Study Evaluation Committee). Report serious or continuing noncompliance to regulatory and funding agencies

Human Research Audit Program Team HRC Gabrielle Gaspard Lauren Odynocki TBD JCTO Alicia Lewis Irene Karpenko Evan O Donovan Contact: researchaudit@med.cornell.edu

Reference WCM Human Research Audit Policy 45CFR46 21CFR312 ICH GCP E6(R2)